Related Experiment Video

Updated: Jun 5, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

346

Unveiling the podocyte-protective effect of sodium-glucose cotransporter-2 inhibitors

Buchun Jiang1,2, Zhiwen Cheng2,3, Dongjie Wang1,2

  • 1Department of Nephrology, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Kidney Research and Clinical Practice
|December 5, 2024
PubMed

Insights

Sodium-glucose cotransporter-2 (SGLT2) inhibitors protect kidneys in diabetic and nondiabetic kidney disease by safeguarding podocytes. These drugs reduce inflammation and oxidative stress, offering potential new treatments for various kidney conditions.

Area of Science:

  • Nephrology
  • Pharmacology
  • Cell Biology

Background:

  • Sodium-glucose cotransporter-2 (SGLT2) inhibitors are recognized for renoprotective effects in diabetic and nondiabetic nephropathy.
  • Randomized controlled trials like DAPA-CKD and EMPA-KIDNEY support their efficacy.

Purpose of the Study:

  • To review clinical and laboratory studies on the podocyte-protective effects of SGLT2 inhibitors.
  • To explore the potential of SGLT2 inhibitors in broader kidney disease applications.

Main Methods:

  • Literature review of clinical and laboratory studies.
  • Analysis of mechanisms of SGLT2 inhibitor action on podocytes.

Main Results:

  • SGLT2 inhibitors protect podocytes by enhancing autophagy and stabilizing podocyte/basement membrane structure.
  • Treatment with SGLT2 inhibitors reduces lipotoxicity, oxidative stress, and inflammation.
  • Emerging evidence supports SGLT2 inhibitor use in nondiabetic podocytopathies like FSGS.

Conclusions:

  • SGLT2 inhibitors demonstrate significant podocyte-protective effects.
  • These findings suggest broader therapeutic potential for SGLT2 inhibitors in managing kidney diseases.
Keywords:
PodocytesPodocytopathiesRenal protectionSodium-glucose transporter 2 inhibitors

More Related Videos

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli12:19

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli

Published on: June 27, 2015

10.9K
Assessment of Kidney Function in Mouse Models of Glomerular Disease09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

17.5K

Related Concept Videos

Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
117.7K
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.3K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
159
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
618